• The world's first tooth-regrowing drug has been approved for human trials. The drug, called Tideglusib, is a small molecule inhibitor that stimulates the growth of stem cells in the dental pulp, allowing teeth to regenerate and repair themselves. This breakthrough could potentially revolutionize dental care, offering a non-invasive alternative to traditional fillings and root canals.

• The drug was developed by a team of researchers at King's College London and has already shown promising results in animal studies. In these studies, Tideglusib was able to stimulate the growth of new dentine, the hard inner layer of the tooth, and repair damage caused by cavities. The researchers are now preparing to conduct the first human clinical trials to test the drug's safety and efficacy in people.

• If the human trials are successful, Tideglusib could provide a significant improvement in dental care, particularly for individuals with tooth decay or other dental issues. The ability to regrow teeth naturally could reduce the need for invasive procedures and improve overall oral health. Additionally, this technology could have broader implications for regenerative medicine, potentially leading to advancements in the treatment of other tissue-related diseases.